Physician profile
Thomas Patrick Sperry
NPI 1578977856
$2,716.71
in general payments reported to CMS, 2019-2025
22 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $101 · 2021: $284 · 2022: $725 · 2023: $681 · 2024: $298 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $639.84 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $335.93 | 2020-2025 | |
| Abbott Laboratories | $321.06 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Pfizer INC. | $310.84 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $203.79 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $139.63 | 2022-2023 | Camzyos |
| Edwards Lifesciences Corporation | $114.16 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $107.04 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $78.23 | 2020-2022 | |
| Novo Nordisk INC | $71.45 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $68.49 | 2022 | |
| Amarin Pharma, INC. | $66.94 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $47.84 | 2021-2022 | |
| Intuitive Surgical, INC. | $40.45 | 2025 | |
| Cvrx, INC. | $39.69 | 2024 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $33.01 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $19.68 | 2023 | Inpefa |
| Surmodics, INC. | $18.40 | 2022 | |
| Angiodynamics, INC. | $17.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.92 | 2024 | |
| Bardy Diagnostics, INC. | $15.19 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sperry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.